S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:TPST

Tempest Therapeutics - TPST Stock Forecast, Price & News

$1.40
+0.09 (+6.87%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.36
$1.43
50-Day Range
$1.14
$2.04
52-Week Range
$1.06
$4.55
Volume
12,757 shs
Average Volume
16,015 shs
Market Capitalization
$14.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Tempest Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,066.7% Upside
$16.33 Price Target
Short Interest
Healthy
0.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.44mentions of Tempest Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.25) to ($2.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

691st out of 989 stocks

Pharmaceutical Preparations Industry

330th out of 480 stocks


TPST stock logo

About Tempest Therapeutics (NASDAQ:TPST) Stock

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Tempest Therapeutics GAAP EPS of -$0.79
Tempest Therapeutics, Inc. Tops Q2 EPS by 13c
TPST Tempest Therapeutics, Inc.
See More Headlines
Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Company Calendar

Last Earnings
11/10/2021
Today
3/23/2023
Next Earnings (Estimated)
5/12/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TPST
Fax
N/A
Employees
14
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$16.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+547.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.23 per share

Miscellaneous

Free Float
9,976,000
Market Cap
$14.62 million
Optionable
Not Optionable
Beta
0.87

Social Links


Key Executives

  • Stephen R. Brady
    Chief Executive Officer & Director
  • Thomas W. DubenskyThomas W. Dubensky
    President & Director
  • Sam Whiting
    Chief Medical Officer & Executive Vice President
  • Darrin Bomba
    Vice President-Clinical Operations
  • Anne Moon
    Senior Vice President













TPST Stock - Frequently Asked Questions

Should I buy or sell Tempest Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares.
View TPST analyst ratings
or view top-rated stocks.

What is Tempest Therapeutics' stock price forecast for 2023?

4 brokers have issued 12 month target prices for Tempest Therapeutics' stock. Their TPST share price forecasts range from $6.00 to $35.00. On average, they anticipate the company's share price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,075.1% from the stock's current price.
View analysts price targets for TPST
or view top-rated stocks among Wall Street analysts.

How have TPST shares performed in 2023?

Tempest Therapeutics' stock was trading at $1.15 at the start of the year. Since then, TPST shares have increased by 20.9% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

Are investors shorting Tempest Therapeutics?

Tempest Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 16,500 shares, an increase of 17.9% from the February 13th total of 14,000 shares. Based on an average daily volume of 16,100 shares, the short-interest ratio is currently 1.0 days. Approximately 0.4% of the company's stock are short sold.
View Tempest Therapeutics' Short Interest
.

When is Tempest Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our TPST earnings forecast
.

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.21) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.16.

When did Tempest Therapeutics' stock split?

Shares of Tempest Therapeutics reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Tempest Therapeutics' stock symbol?

Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST."

Who are Tempest Therapeutics' major shareholders?

Tempest Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode.
View institutional ownership trends
.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tempest Therapeutics' stock price today?

One share of TPST stock can currently be purchased for approximately $1.39.

How much money does Tempest Therapeutics make?

Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $14.62 million.

How can I contact Tempest Therapeutics?

Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at (415) 798-8589 or via email at stephanie@sternir.com.

This page (NASDAQ:TPST) was last updated on 3/24/2023 by MarketBeat.com Staff